Carroll W L, Lowder J N, Streifer R, Warnke R, Levy S, Levy R
J Exp Med. 1986 Nov 1;164(5):1566-80. doi: 10.1084/jem.164.5.1566.
Using isolated idiotype (Id) protein we generated panels of antibodies in two patients with follicular lymphoma, one of whom had never received prior chemo-or radiotherapy. Flow cytometry and frozen section tissue staining of tumor with these monoclonal antibodies (mAb) revealed multiple subpopulations within each tumor. Individual mAb stained between 7% and 83% of surface Ig+ cells in the tumor samples. These subpopulations were overlapping and no single antibody recognized all the tumor cells. However, combinations of antibodies seemed to capture total tumor in both cases. In some instances, the percentage of tumor stained by a single mAb varied over time, and differed between lymph nodes sampled at the same time. Because a single species of Id protein was used to generate mAb in each case, it appears that the antibodies were directed against idiotopes variably shared by different populations within each tumor, and this was confirmed by crossblocking studies. Tumor cells from one patient were fused to a nonsecreting heteromyeloma line K6H6/B5, and most of the resulting hybrids secreted Id protein. Four mAb were used to screen the Id proteins secreted by these hybrids, and 11 different variants (16 maximal) were found. Southern blot analysis of rearranged Ig genes was done in two hybrids and biopsy material. Identically rearranged light-chain genes were seen but it appeared as though extensive somatic variation had occurred in heavy chain genes. These studies indicate that: striking Id variation can exist at diagnosis in untreated patients, the percentage of tumor represented by an individual variant may change with time and may differ between tumor sampled from different anatomical locations, and somatic variation appears to be responsible for the observed heterogeneity. Although this degree of variation makes anti-Id antibody therapy more difficult, appropriate combinations of mAb should be more efficacious than single antibodies in such cases.
我们使用分离的独特型(Id)蛋白,在两名滤泡性淋巴瘤患者中制备了抗体组,其中一名患者从未接受过化疗或放疗。用这些单克隆抗体(mAb)对肿瘤进行流式细胞术和冷冻切片组织染色,结果显示每个肿瘤内存在多个亚群。在肿瘤样本中,单个mAb可染色7%至83%的表面Ig +细胞。这些亚群相互重叠,没有一种单一抗体能识别所有肿瘤细胞。然而,在这两个病例中,抗体组合似乎能捕获全部肿瘤。在某些情况下,单个mAb染色的肿瘤百分比随时间变化,且在同一时间采集的淋巴结之间也存在差异。由于在每种情况下都使用单一物种的Id蛋白来制备mAb,因此似乎这些抗体是针对每个肿瘤内不同群体可变共享的独特型表位,交叉阻断研究证实了这一点。将一名患者的肿瘤细胞与非分泌性异源骨髓瘤细胞系K6H6/B5融合,大多数所得杂交瘤分泌Id蛋白。用四种mAb筛选这些杂交瘤分泌的Id蛋白,发现了11种不同变体(最多16种)。对两个杂交瘤和活检材料进行了重排Ig基因的Southern印迹分析。观察到轻链基因重排相同,但重链基因似乎发生了广泛的体细胞变异。这些研究表明:未经治疗的患者在诊断时可能存在显著的Id变异,单个变体所代表的肿瘤百分比可能随时间变化,且在不同解剖部位采集的肿瘤之间可能存在差异,体细胞变异似乎是观察到的异质性的原因。尽管这种变异程度使抗Id抗体治疗更加困难,但在这种情况下,适当的mAb组合应该比单克隆抗体更有效。